Passage Bio (PASG) has shared an update.
Mark Forman, the Chief Medical Officer of the Company, has chosen to resign effective August 2, 2024, without any conflicts over the Company’s operations, policies, or practices. In a strategic move, the Company announced Susan Browne as the new Chief Scientific Officer and Stuart Henderson as Chief Business Officer, effective August 1, 2024. Both executives have significantly shaped the Company’s direction, with Browne enhancing the clinical portfolio and Henderson building valuable financial and business relationships, steering the focus towards researching progranulin’s role in adult neurodegenerative diseases.
See more data about PASG stock on TipRanks’ Stock Analysis page.
